Table 4.
Summary of treatments received and outcome of study population.
| Parameters | Thal, n (%) | SCD, n (%) |
|---|---|---|
| Hospitalization | n = 26 | n = 162 |
| Yes | 16 (61.5) | 139 (85.8) |
| No | 10 (38.5) | 23 (14.2) |
| Treatments | n = 12 | n = 43 |
| Hydroxychloroquine | 6 (50.0) | 26 (60.5) |
| Antibiotics* | 9 (75.5) | 28 (65.1) |
| Anti-viral | 5 (41.7) | 0 (0) |
| Disease modifying agent | ||
| Tocilizumab | 1 (8.3) | 4 (9.3) |
| Anakinra | 1 (8.3) | 3 (7.0) |
| Glucocorticoid | 1 (8.3) | 3 (7.0) |
| Oxygen support | n = 26 | n = 162 |
| No oxygen required | 15 (57.7) | 118 (72.8) |
| Non-invasive | 11 (42.3) | 33 (20.4) |
| Invasive | 0 (0) | 11 (6.8) |
| Transfusion | n = 26 | n = 162 |
| No transfusion required | 21 (80.8) | 107 (66.0) |
| Packed cell transfusion | 5 (19.2) | 45 (27.8) |
| Exchange transfusion | N/A | 4 (2.5) |
| Packed cell and exchange transfusion | N/A | 6 (3.7) |
| Treatment outcome | n = 84 | n = 162 |
| Recovered | 71 (84.5) | 158 (97.5) |
| Death | 13 (15.5) | 4 (2.5) |
SCD, sickle cell disease; Thal, thalassemia; n, number; N/A, not applicable.
*
Types of antibiotics used includes cephalosporin, macrolide, fluoroquinolone, beta-lactamase and tetracycline.